Everyday HealthBispecific Antibody Shows Promise in R/R Multiple Myeloma

Publication: The LancetDesign: Open-label, single-arm study of 157 patients who had undergone a median of six previous lines of therapy and who received at least one dose of teclistamab; 40 patients received the recommended phase II dose of teclistamabResults: Of the 40 receiving the phase II dose, 58% achieved a very good partial response or […]

American Society of HematologyClonal Hematopoiesis in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Source: Blood AdvancesKey Points: In a cohort of 154 patients with NHL or MM receiving CAR T-cells, clonal hematopoiesis of indeterminate potential (CHIP) was present in 48%. Although associated with worse prognosis in these patients receiving autologous transplantation, no such association was seen in these patients receiving CAR T. Instead, the authors saw increased rates […]

American Society of Clinical OncologyWhat “The Princess Bride” Teaches Us About Outcomes in Multiple Myeloma

“It’s inconceivable!” This famous line and exchange from the 1987 classic film The Princess Bride, along with the fates of the characters Vizzini and Inigo Montoya, provide the fulcrum for this Journal of Clinical Oncology (JCO) editorial, which highlights the phase III TOURMALINE-MM1 trial and its seemingly “negative” findings in multiple myeloma (MM). Are we […]

Millennium Medical PublishingCurrent Antibody-Based Therapies for the Treatment of Multiple Myeloma

Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing  the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.